The FDA approved imlunestrant plus abemaciclib for ESR1-mutated advanced breast cancer. Median progression-free survival doubled in an ESR1-mutated subgroup.
Inluriyo Plus Verzenio Wins Full FDA Approval for ESR1 Mutated Advanced Breast Cancer After Progression on Endocrine Therapy
by | Sep 19, 2026 | Uncategorized | 0 comments
Recent Comments